ATIR (donor T-lymphocytes depleted ex vivo of host alloreactive T-cells)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ATIR (donor T-lymphocytes depleted ex vivo of host alloreactive T-cells), covering 2021-01-12 to 2021-01-12. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor [Phase 2]